Feb 5 (Reuters) - Zenas Biopharma Inc ZBIO.O:
ZENAS BIOPHARMA : TOPLINE RESULTS FROM PHASE 2 TRIAL IN RELAPSING MULTIPLE SCLEROSIS (MOONSTONE) EXPECTED IN Q3 2025
ZENAS BIOPHARMA :TOPLINE RESULTS FROM PIVOTAL PHASE 3 TRIAL IN IMMUNOGLOBULIN G4-RELATED DISEASE (INDIGO) EXPECTED YEAR-END 2025
Source text: ID:nGNX3GBN3c
Further company coverage: ZBIO.O